Référence
Ariel Stern (Harvard Business School), « Regulatory Incentives for Innovation: The FDA’s Breakthrough Therapy Designation », Workshop: Innovation, regulation and organization in healthcare, Paris, 2022.
Voir aussi
Publié dans
Workshop: Innovation, regulation and organization in healthcare, Paris, 2022